# Jamie Macfarlane

> Jamie Macfarlane is a seed investor at Creator Fund backing Biotechnology and Life Science. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Creator Fund](https://shizune.co/investors/profile/creator-fund)
- Location: London, United Kingdom
- Total investments: 8
- Last investment: Apr 2026
- Lead investor: 63%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jamiemacfarlane/
- X (Twitter): https://twitter.com/MacfarlaneJamie
- Website: https://x.com/MacfarlaneJamie
- Facebook: https://www.facebook.com/jamiemacfarlane4WN

Jamie Macfarlane is a seed investor at Creator Fund in London focused on Biotechnology and Life Science. Jamie Macfarlane is based out of London, England and is the CEO & Founder of Creator Fund. Jamie previously worked at WPP as a Director of Transformation. Jamie Macfarlane attended the Stanford University Graduate School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Life Science | 2 | 25% |
| Chemical | 1 | 13% |
| Internet | 1 | 13% |
| Software | 1 | 13% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 38% |
| Pre-Seed | 3 | 38% |
| Series A | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Entelo Bio | Precision Medicine | $4M | Seed | Apr 24, 2026 |  |
| Anzen Industries | Anzen Industries focuses on biotech innovation, engineering molecular resilience by stabilizing enzymes for industrial reactions. | $2.3M | Pre-Seed | Jan 19, 2026 |  |
| Ovo Labs | Ovo Labs is developing therapeutics that boost egg quality to enhance IVF success, technology aims to extend the timeline when the chances of conception are high. | $5.3M | Seed | Apr 24, 2025 |  |
| Baseimmune | Baseimmune is a biotech startup founded to create the next generation of vaccines. | $11.4M | Series A | Feb 26, 2024 |  |
| Didimi | Didimi is a developer of a digital twins and information management platform designed for the construction industry. | $944.4K | Pre-Seed | Feb 14, 2024 |  |
| Myria Biosciences | Myria have developed a genetically engineered platform that allows for the discovery of complex natural product molecules which have pharmaceutical applications. They screen tens of millions of compounds for identification and optimisation of drug lead candidates. | $1.9M | Pre-Seed | Jan 05, 2024 |  |
| Baseimmune | Baseimmune is a biotech startup founded to create the next generation of vaccines. | $4.8M | Seed | Nov 02, 2021 |  |
| Baseimmune | Baseimmune is a biotech startup founded to create the next generation of vaccines. | $947.6K | Seed | Apr 01, 2021 |  |

8 of 8 investments shown.

## Co-investors
- [Maki.vc](https://shizune.co/investors/profile/maki-vc) — VC Fund, 3 deals together
- [Rockmount Seed Investments Limited](https://shizune.co/investors/profile/rockmount-seed-investments-limited) — VC Fund, 3 deals together
- [Beast Ventures](https://shizune.co/investors/profile/beast-ventures) — VC Fund, 2 deals together
- [Hoxton Ventures](https://shizune.co/investors/profile/hoxton-ventures) — VC Fund, 2 deals together
- [LocalGlobe](https://shizune.co/investors/profile/localglobe) — VC Fund, 2 deals together
- [Ahren Innovation Capital](https://shizune.co/investors/profile/ahren-innovation-capital) — VC Fund, 1 deal together

## About Creator Fund

VC Fund · London, United Kingdom

Creator Fund invests in founders building companies on the frontier of what's possible. We are deep technology experts and believe before others understand. We think the next generation of technology European unicorns will be built out of university innovation and have teams across 24 campuses to back pioneering scientific founders first.

3 contacts available at Creator Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Alexandra Ntemourtsidou | COO | https://shizune.co/investors/profile/alexandra-ntemourtsidou |
| Jamie Macfarlane | CEO & Founder | https://shizune.co/investors/profile/jamie-macfarlane |
| Louise Mackie | LP | https://shizune.co/investors/profile/louise-mackie |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Jamie Macfarlane invest in?

Jamie Macfarlane invests primarily in Biotechnology, Life Science and Chemical startups, most often at Seed and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jamie Macfarlane last invest?

The most recent investment recorded for Jamie Macfarlane closed in Apr 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co